Publications by authors named "Francesca Cicero"
Omalizumab in middle-aged or older patients with severe allergic asthma-COPD overlap.
Postepy Dermatol Alergol
February 2022
Article Synopsis
- Biological therapies like omalizumab can effectively treat severe allergic asthma in older patients, particularly those with asthma-COPD overlap.
- A study involving 11 patients showed that omalizumab improved symptoms within the first year, as evidenced by better Asthma Control Test (ACT) scores and fewer exacerbations.
- Continued treatment resulted in sustained improvements in asthma control and quality of life, indicating that omalizumab is a viable option for older patients with severe asthma.
IL-33 is a recently identified cytokine, encoded by the IL-33 gene, which is a member of the IL-1 family that drives the production of T-helper-2 (Th-2)-associated cytokines. Serum levels of IL-33 have been reported to be up-regulated in various T-helper (Th)-1/Th-17-mediated diseases, such as psoriasis, rheumatoid arthritis, and inflammatory bowel. To investigate whether cytokine imbalance plays a role in the pathogenesis of vitiligo, we performed a case-control association study by enzyme-linked immunosorbent assay of IL-33 in our patients.
View Article and Find Full Text PDF